These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 15478040)
1. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Nicholls S; Lundman P Semin Vasc Med; 2004 May; 4(2):187-95. PubMed ID: 15478040 [TBL] [Abstract][Full Text] [Related]
2. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Linsel-Nitschke P; Tall AR Nat Rev Drug Discov; 2005 Mar; 4(3):193-205. PubMed ID: 15738977 [TBL] [Abstract][Full Text] [Related]
3. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
4. [The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations]. Birjmohun RS; van der Steeg WA; Stroes ES; Kastelein JJ Ned Tijdschr Geneeskd; 2006 Oct; 150(41):2245-50. PubMed ID: 17076358 [TBL] [Abstract][Full Text] [Related]
6. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol. Lamarche B; Lewis GF Can J Cardiol; 1998 Jun; 14(6):841-51. PubMed ID: 9676170 [TBL] [Abstract][Full Text] [Related]
7. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
8. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Miller M; Ginsberg HN; Schaefer EJ Am J Cardiol; 2008 Apr; 101(7):1003-8. PubMed ID: 18359322 [TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of niacin. Kamanna VS; Kashyap ML Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237 [TBL] [Abstract][Full Text] [Related]
13. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Zambon A; Gervois P; Pauletto P; Fruchart JC; Staels B Arterioscler Thromb Vasc Biol; 2006 May; 26(5):977-86. PubMed ID: 16424352 [TBL] [Abstract][Full Text] [Related]
14. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Vergès BL Diabetes Metab; 1999 Jun; 25 Suppl 3():32-40. PubMed ID: 10421991 [TBL] [Abstract][Full Text] [Related]
15. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Hayashi T; Hirano T; Yamamoto T; Ito Y; Adachi M Metabolism; 2006 Jul; 55(7):879-84. PubMed ID: 16784958 [TBL] [Abstract][Full Text] [Related]